Teen anxiety: what the evidence says actually helps

Anxiety disorders are among the most common mental-health conditions in young people, and the reassuring headline is that they respond to treatment. The best trial evidence points to two effective options — cognitive behavioural therapy (CBT) and a selective serotonin-reuptake inhibitor (SSRI) — with the combination working best in the largest study [s1]. Talking therapy on its own also clearly beats no treatment across dozens of trials [s2]. What the evidence does not support is waiting anxiety out, or assuming a teenager will simply grow out of a disorder that is interfering with school, friendships, or sleep.

The trial that anchors the field

The Child/Adolescent Anxiety Multimodal Study (CAMS) randomly assigned 488 children aged 7 to 17 with separation anxiety disorder, generalised anxiety disorder, or social phobia to one of four groups for 12 weeks: CBT alone, sertraline alone, the two combined, or placebo [s1]. The combination came out clearly ahead.

The proportions rated as very much or much improved were 80.7% for combination therapy, 59.7% for CBT alone, and 54.9% for sertraline alone, against 23.7% for placebo [s1]. All three active treatments beat placebo, and the combination was superior to either treatment on its own [s1]. On a second, symptom-based anxiety scale the pattern held: the combination outperformed CBT, which was roughly equivalent to sertraline, and all three beat placebo [s1].

The safety question, stated plainly

Trials of medication in young people carry an unavoidable safety question, and CAMS addressed it directly. Adverse events, including suicidal and homicidal ideation, were no more frequent in the sertraline group than in the placebo group, and no child attempted suicide during the trial [s1]. There was also less insomnia, fatigue, sedation, and restlessness with CBT than with sertraline [s1].

That comparison is part of why therapy is often the starting point: it carries a lighter side-effect profile. But it is not a reason to rule out medication, which was well tolerated in this trial and, combined with CBT, helped the most children [s1]. The right balance depends on severity, preference, and access, and it is a decision for a clinician and family together.

What the wider evidence base adds

A single trial, however large, is not the whole story. A Cochrane review pooled 87 studies with 5,964 participants to test CBT specifically against comparisons such as waiting lists and usual care [s2]. Compared with waitlist or no treatment, CBT probably increases remission of the primary anxiety diagnosis after treatment: 49.4% of children given CBT were in remission versus 17.8% of those who waited (odds ratio 5.45, 95% confidence interval 3.90 to 7.60), which the reviewers rated as moderate-quality evidence [s2]. The number needed to treat was 3 — roughly one extra child recovering for every three treated [s2].

The review was more cautious about how CBT compares with active alternatives and usual care, where the evidence was thinner and lower in certainty [s2]. The dependable conclusion is the strong one against no treatment: doing nothing is the option the evidence most clearly rejects.

How to read this without overreaching

The honest summary is that adolescent anxiety is treatable, that CBT and SSRIs both work, and that combining them helped most in the largest trial — while therapy alone is a well-supported and lower-risk starting point [s1] [s2]. What the evidence does not support is treating ordinary nerves as illness, or reaching for medication without also offering therapy and follow-up.

The limits bound the claims. CAMS ran for 12 weeks, so it speaks to short-term treatment rather than years of a young person's life, and it studied three specific anxiety disorders rather than every kind of worry [s1]. The Cochrane review's clearest finding is against waitlists; its comparisons with other active treatments rest on lower-certainty evidence [s2]. Neither addresses prevention or milder, self-limiting anxiety.

This article is informational and is not medical advice. It does not recommend any medication, dose, or therapy for an individual, and no one should start or stop treatment based on it. A young person who is struggling with anxiety, or a family concerned about one, should seek help from a qualified clinician; if there is any immediate risk of harm, contact local emergency services or a crisis line.